Immunowake is a biotechnology company developing bi-specific antibodies that activate T-cells by utilizing a CD3 platform and a unique VEGF trap design to enhance anti-tumor responses. The company targets patients who do not respond to existing immunotherapies by overcoming tumor-induced immune suppression.
Funding
$23.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HISCFounders
Product
Problem
Existing immunotherapies are ineffective for a significant portion of cancer patients due to tumor-induced immune suppression. These patients lack effective treatment options to stimulate their immune system to fight the tumor.
Solution
Immunowake is developing bi-specific antibodies designed to activate T-cells and enhance anti-tumor responses, particularly in patients who do not respond to existing immunotherapies. The company utilizes a CD3 platform to generate bi-specific antibodies that activate T-cells in an antigen-dependent manner. Their unique VEGF trap design exhibits synergistic anti-tumor effects against various cancers by overcoming suppressive signals released by the tumor. Immunowake employs cell-based assays to rapidly screen for the biological activity of bi-specific antibodies and identify new surface proteins that can be targeted through immunotherapy.
Target Audience
The primary target audience includes cancer patients who are unresponsive to current immunotherapy treatments, as well as researchers and clinicians focused on developing novel immunotherapeutic approaches.
Features
- CD3 bi-specific platform for generating antibodies that activate T-cells.
- Unique VEGF trap design to enhance anti-tumor effects.
- Cell-based assays for rapid screening of bi-specific antibody activity.
- Targets tumor-induced immune suppression to improve immunotherapy response.